Actinium Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Summary Compensation Table
The following table provides information regarding the compensation earned during the years ended December 31, 2023 and 2022 for our named executive officers.
| Name/Position · Year · Salary · Bonus (1) · Option Awards (2) · All Other Compensation · Total | |||||||
|---|---|---|---|---|---|---|---|
| Sandesh Seth | 2023 | $705,000 | $500,000 | $3,500,000 | $ | - | $4,705,000 |
| Chairman and Chief Executive Officer(3) | 2022 | $665,000 | $480,000 | $2,875,167 | $ | - | $4,020,167 |
| Steve O’Loughlin | 2023 | $420,000 | $170,000 | $900,000 | $ | - | $1,490,000 |
| Chief Financial Officer | 2022 | $400,000 | $185,000 | $891,144 | $ | - | $1,476,144 |
| (1) | The bonus disclosed in this column relates to performance in the prior year, but was determined and approved by the Board and was paid in the year disclosed. |
| (2) | The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted during the indicated year. These amounts have been calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 7 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the NEOs. |
| (3) | In addition to the foregoing, on August 17, 2022, Mr. Seth was granted an award of 300,000 restricted stock units, or RSUs, which were granted in exchange for warrants that Mr. Seth received for services provided to the Company prior to becoming employed by Actinium. These warrants were granted on December 17, 2012 and vested and became exercisable on the 12-month anniversary of the grant date. The warrants were in the money for their entire existence since vesting. Mr. Seth was appointed Chairman of the Board in October 2013, became Executive Chairman in August 2014 and Chief Executive Officer in June 2017. Mr. Seth refrained from exercising the warrants in order to be aligned with the long-term interests of the Company and shareholders. In November 2018, the Board extended the expiration of Mr. Seth’s warrants to February 2022. In February 2022, the Company requested that Mr. Seth not exercise the warrants to maintain alignment with the long-term interests of the Company. In exchange for refraining from exercising these warrants, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life based on the Black-Scholes option-pricing model to continue to align Mr. Seth with the long-term interest of the Company and shareholders. The RSU grant was detailed on Form 4 filed with the SEC on August 19, 2022. |
Narrative Disclosure to Summary Compensation Table
For a discussion of the material terms of each named executive officer’s employment agreement or arrangement, refer to the sections above titled “Directors, Executive Officers and Corporate Governance—Chief Executive Officer Compensation” and “Directors, Executive Officers and Corporate Governance—Chief Financial Officer/Principal Financial Officer Compensation.”
On December 28, 2023, Mr. Seth was granted an option to purchase 984,367 shares of common stock and Mr. O’Loughlin was granted an option to purchase 253,123 shares of common stock. The options have an exercise price of $5.00 per share and expire on December 28, 2033. Pursuant to the terms of the 2019 Stock Plan, 2% of the options will vest each month from the respective dates of grants until fully vested.
On August 17, 2022, Mr. Seth was issued 300,000 restricted stock units, or RSUs, in exchange for warrants issued to him for services provided to the Company prior to being employed by Actinium. These RSUs vest at the earliest of a change of control event, the termination of the recipient’s continuous service status for any reason other than by the Company for cause and the third anniversary of the date of the grant.
On July 1, 2022, Mr. Seth was granted an option to purchase 827,366 shares of common stock and Mr. O’Loughlin was granted an option to purchase 256,438 shares of common stock. The options have an exercise price of $4.96 per share and expire on July 1, 2032. Pursuant to the terms of the Company’s Amended and Restated 2019 Stock Plan, 2% of the options will vest each month from the respective dates of grants until fully vested.
Director Compensation
The following table sets forth the compensation of our non-employee directors for the year ended December 31, 2023:
| Name | Fees Earned | Stock Awards | Option Awards (1)(2) | All Other Compensation | Total |
|---|---|---|---|---|---|
| Jeffrey W. Chell | $51,000 | - | $250,000 | - | $51,000 |
| David Nicholson | $63,000 | - | $250,000 | - | $63,000 |
| Ajit J. Shetty | $58,500 | - | $250,000 | - | $58,500 |
| Richard Steinhart | $63,000 | - | $250,000 | - | $63,000 |
| (1) | The dollar amounts in this column represent the aggregate grant date fair value of options granted during 2023. These amounts have been calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 7 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the Directors. |
| (2) | At December 31, 2023, the aggregate number of option awards outstanding for each director was as follows: (i) for Dr. Chell, 182,484, (ii) for Dr. Nicholson, 185,817, (iii) for Dr. Shetty, 182,484, and (iv) for Mr. Steinhart, 185,817. |
Our non-employee directors are paid an annual fee of $40,000 and in most years, receive option grants. Dr. Nicholson as Lead Director receives an additional annual fee of $10,000. Board committee members receive the following compensation:
| BOD Committee | Chairman | Member |
|---|---|---|
| Audit | $20,000 | $6,000 |
| Compensation | $10,000 | $5,000 |
| Nominating and Corporate Governance | $7,500 | $3,000 |
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END - 2023
The following table sets forth all unexercised stock options and unvested restricted stock units that have been awarded to our named executives by the Company that were outstanding as of December 31, 2023.
| Option Awards · Stock Awards | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Name (a) · Number of Securities Underlying Unexercised Options (#) (Exercisable) (b) · Number of Securities Underlying Unexercised Options (#) (Unexercisable) (c) · Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)(d) · Option Exercise Price ($) (e) · Option Expiration Date (f) · Number of Shares or Units of Stock That Have Not Vested (#) (g) · Market Value of Shares or Units of Stock That Have Not Vested ($) (h) · Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) (i) · Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) (j) | ||||||||||
| Sandesh Seth | 9,333 | (1) | - | - | 183.90 | 9/23/2024 | - | - | - | - |
| 5,000 | (1) | - | - | 107.40 | 2/15/2025 | - | - | - | - | |
| 16,666 | (1) | - | - | 59.70 | 4/15/2026 | - | - | - | - | |
| 24,998 | (1) | - | - | 41.70 | 3/14/2027 | - | - | - | - | |
| 33,333 | (1) | - | - | 23.497 | 7/13/2028 | - | - | - | - | |
| 50,000 | (1) | - | - | 6.96 | 7/12/2029 | - | - | - | - | |
| 111,240 | (2) | 27,822 | - | 9.55 | 8/12/2030 | - | - | - | - | |
| 167,498 | (2) | 142,684 | - | 6.07 | 9/01/2031 | - | - | - | - | |
| 281,304 | (2) | 546,062 | - | 4.96 | 7/01/2032 | - | - | - | - | |
| - | (2) | 984,367 | - | 5.00 | 12/28/2033 | - | - | - | - | |
| - | - | - | - | - | 300,000 | 1,524,000 | - | - | ||
| Steve O’Loughlin | 3,333 | (1) | - | - | 53.70 | 9/28/2025 | - | - | - | - |
| 1,666 | (1) | - | - | 59.70 | 4/15/2026 | - | - | - | - | |
| 3,333 | (1) | - | - | 41.70 | 3/14/2027 | - | - | - | - | |
| 8,833 | (1) | - | - | 23.497 | 7/13/2028 | - | - | - | - | |
| 13,333 | (1) | - | - | 6.96 | 7/12/2029 | - | - | - | - | |
| 47,240 | (2) | 11,826 | - | 9.55 | 8/12/2030 | - | - | - | - | |
| 58,030 | (2) | 49,433 | - | 6.07 | 9/01/2031 | - | - | - | - | |
| 87,188 | (2) | 169,250 | - | 4.96 | 7/01/2032 | - | - | - | - | |
| - | (2) | 253,123 | - | 5.00 | 12/28/2033 | - | - | - | - | |
| (1) | Fully vested. |
| (2) | Pursuant to the terms of the Company’s 2013 Stock Plan or 2019 Stock Plan, 2% of these options vest each month from the date of grant. |
Indemnification of Directors and Officers
Section 102(b)(7) of the Delaware General Corporation Law allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides for this limitation of liability.
Section 145 of the General Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation may indemnify any persons who are, or were, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or directors has actually and reasonably incurred.
Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.
Our bylaws provide that we will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware. Expenses (including attorneys’ fees) incurred by an officer or director of the Corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company as authorized under Delaware law. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Company deems appropriate.
The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.
We maintain a general liability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers. We have also entered into Indemnification Agreements with our executive officers and directors.
At the present time, there is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnification would be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.